In the past week, RCKT stock has gone down by -0.21%, with a monthly decline of -12.16% and a quarterly plunge of -15.15%. The volatility ratio for the week is 4.68%, and the volatility levels for the last 30 days are 4.14% for Rocket Pharmaceuticals Inc. The simple moving average for the past 20 days is -5.10% for RCKT’s stock, with a 2.57% simple moving average for the past 200 days.
Is It Worth Investing in Rocket Pharmaceuticals Inc (NASDAQ: RCKT) Right Now?
Moreover, the 36-month beta value for RCKT is 1.09. Analysts have varying opinions on the stock, with 1 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for RCKT is 83.98M and currently, short sellers hold a 12.52% of that float. On April 25, 2024, RCKT’s average trading volume was 712.20K shares.
RCKT) stock’s latest price update
Rocket Pharmaceuticals Inc (NASDAQ: RCKT)’s stock price has dropped by -0.17 in relation to previous closing price of 23.67. Nevertheless, the company has seen a loss of -0.21% in its stock price over the last five trading days. Seeking Alpha reported 2024-04-05 that Rocket Pharmaceuticals, Inc. has potential FDA approvals for its gene therapies on the horizon. The company focuses on developing gene therapies for rare diseases, targeting a market that is expected to triple in value by the end of the decade. Rocket’s pipeline includes promising therapies for severe leukocyte adhesion deficiency-I, Danon Disease, and Fanconi Anemia, among others.
Analysts’ Opinion of RCKT
Many brokerage firms have already submitted their reports for RCKT stocks, with Goldman repeating the rating for RCKT by listing it as a “Neutral.” The predicted price for RCKT in the upcoming period, according to Goldman is $39 based on the research report published on April 02, 2024 of the current year 2024.
Cantor Fitzgerald, on the other hand, stated in their research note that they expect to see RCKT reach a price target of $65. The rating they have provided for RCKT stocks is “Overweight” according to the report published on October 24th, 2023.
Morgan Stanley gave a rating of “Overweight” to RCKT, setting the target price at $45 in the report published on February 01st of the previous year.
RCKT Trading at -12.52% from the 50-Day Moving Average
After a stumble in the market that brought RCKT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -27.35% of loss for the given period.
Volatility was left at 4.14%, however, over the last 30 days, the volatility rate increased by 4.68%, as shares sank -11.03% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -21.21% lower at present.
During the last 5 trading sessions, RCKT fell by -0.21%, which changed the moving average for the period of 200-days by +20.75% in comparison to the 20-day moving average, which settled at $24.75. In addition, Rocket Pharmaceuticals Inc saw -21.15% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at RCKT starting from Militello John, who sale 833 shares at the price of $22.87 back on Apr 22 ’24. After this action, Militello John now owns 54,406 shares of Rocket Pharmaceuticals Inc, valued at $19,051 using the latest closing price.
SOUTHWELL DAVID P, the Director of Rocket Pharmaceuticals Inc, sale 10,000 shares at $24.05 during a trade that took place back on Apr 15 ’24, which means that SOUTHWELL DAVID P is holding 114,784 shares at $240,520 based on the most recent closing price.
Stock Fundamentals for RCKT
Current profitability levels for the company are sitting at:
- -25.18 for the present operating margin
The net margin for Rocket Pharmaceuticals Inc stands at -23.49. The total capital return value is set at -0.5. Equity return is now at value -50.01, with -43.93 for asset returns.
Based on Rocket Pharmaceuticals Inc (RCKT), the company’s capital structure generated 0.05 points at debt to capital in total, while cash flow to debt ratio is standing at -7.78. The debt to equity ratio resting at 0.05. The interest coverage ratio of the stock is -277.12.
Currently, EBITDA for the company is -252.56 million with net debt to EBITDA at 0.13. When we switch over and look at the enterprise to sales, we see a ratio of 204.4. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.80.
Conclusion
To wrap up, the performance of Rocket Pharmaceuticals Inc (RCKT) has been bad in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
